๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Tianjin

940 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
NCT07475026HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 3
198
Tianjin
2026-06-09
Not yet open
Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL๏ผšStop Trial 2.0
NCT07682415CLL / SLL
Yi Shuhua
Phase 2
60
Shenzhen, Zhengzhou, Changsha, Nanjing, Nanchang, Jinan, Tianjin
2026-06-08
Recruiting
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
NCT07589569Pancreatic Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 2
92
Nanjing, Tianjin
2026-06-04
Recruiting
Phase I Study of HRS-3005 in B-cell Malignancies
NCT07556822B-cell Malignancy
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
190
Tianjin
2026-06-03
Recruiting
Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
NCT07618936PD-L1 Gene Mutation, PD-L1 Gene Amplification, PD-L1-related Disease, Positron Emission Tomography
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2026-06-01
Not yet open
Phase I Study of FXS0683 in the Treatment of Blood Tumors
NCT07616089B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
228
Tianjin
2026-06-01
Not yet open
Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT07493993ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
26
Tianjin
2026-06-01
Not yet open
A Long-term Efficacy and Safety of NTQ5082 Capsules
NCT07177872Paroxysmal Nocturnal Hemoglobinuria
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 3
78
Tianjin
2026-06
Not yet open
A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
NCT07601048KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
Shandong Suncadia Medicine Co., Ltd.
Phase 3
450
Tianjin
2026-06
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Nanchang, Shenzhen, Tianjin
2026-05-31
Recruiting
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
NCT07454226Ph-Like, Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
92
Tianjin
2026-05-30
Not yet open
Sonazoid CEUS for Early HCC Surveillance
NCT07590284Liver Cirrhosis, Liver Fibrosis
Tianjin Third Central Hospital
Not applicable
556
Tianjin
2026-05-30
Not yet open
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
NCT07625527Bladder (Urothelial, Transitional Cell) Cancer, Non Muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Phase 2
120
Tianjin, Xingtai
2026-05-30
Recruiting
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
NCT07512583Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
178
Beijing, Harbin, Tianjin
2026-05-27
Recruiting
Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
NCT07632118Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3
288
Tianjin
2026-05-22
Recruiting
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
NCT07614477Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS)
Everest Medicines (China) Co.,Ltd.
Phase 2
45
Beijing, Tianjin
2026-05-20
Recruiting
IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
NCT07799922IRE
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2026-05-20
Recruiting
R-PMDT Regimen in Newly Diagnosed PCNSL
NCT07604987Primary Central Nervous System (CNS) Lymphoma
Zou Dehui
Phase 2
33
Tianjin
2026-05-20
Recruiting
IRE After Chemotherapy for Locally Advanced Pancreatic Cancer
NCT07799935IRE
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2026-05-20
Recruiting
SIM0613 in Participants With Advanced Solid Tumors
NCT07618260Advanced Solid Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
294
Tianjin
2026-05-15
Not yet open
The Effect of Intraoperative Esketamine Infusion on Pruritus in Elderly Surgical Patients
NCT07597486Senile Pruritus
Tianjin Medical University General Hospital
Not applicable
200
Tianjin
2026-05-15
Active, closed
LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia
NCT07350486Hypertension, Diabetes, Dyslipidemia
First Hospital of China Medical University
Not applicable
6,800
Cangzhou, Suzhou, Panjin, Shenyang, Jinzhou, Tianjin
2026-05-14
Recruiting
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT07591155Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Tianjin
2026-05-13
Recruiting
Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device
NCT07561567Lung Cancer, Non-Small Cell
Tianjin Medical University Cancer Institute and Hospital
Observational
50
Tianjin
2026-05-10
Recruiting
Efficacy of Liposomal Bupivacaine for Transversus Abdominis Plane Block
NCT07577934Postoperative Pain, Liposomal Bupivacaine
Tianjin First Central Hospital
Not applicable
86
Tianjin
2026-05-10
Recruiting
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NCT07490288AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
27
Tianjin
2026-05-08
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea
Novo Nordisk A/S
Phase 3
300
Beijing, Guangzhou, Shenzhen, Luoyang, Nanjing, Tianjin
2026-05-05
Not yet open
The Effect of a Single Intravenous Injection of Esketamine During Cesarean Section on Postoperative Pruritus in Patients With Intrahepatic Cholestasis of Pregnancy
NCT07560722Intrahepatic Cholestasis of Pregnancy
Tianjin Medical University General Hospital
Not applicable
160
Tianjin
2026-05-05
Recruiting
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
NCT07594925Rectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
130
Tianjin
2026-05-01
Recruiting
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
NCT07528274NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2026-05-01
Not yet open
A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
NCT07510594Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
48
Tianjin
2026-05-01
Not yet open
A Preliminary Efficacy of SNA028 in Patients With Advanced Colorectal Cancer Positive for GPA33
NCT07590856Colorectal Cancer
SmartNuclide Biopharma
Phase EARLY_PHASE1
20
Tianjin
2026-05-01
Recruiting
SNRK & Vascular Endothelial Aging
NCT07591337Vascular Aging
Tianjin Medical University
Observational
180
Tianjin
2026-05-01
Recruiting
A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)
NCT07496372Heart Failure
HELP Therapeutics Co., Ltd.
Phase 3
80
Tianjin
2026-04-30
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 2
50
Zhengzhou, Tianjin
2026-04-28
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NCT07416604Hemophilia A
Hoffmann-La Roche
Phase 3
360
Guangzhou, Chengdu, Tianjin
2026-04-27
Active, closed
Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.
NCT07654530Biliary Tract Cancers (BTC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
107
Tianjin
2026-04-24
Not yet open
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
NCT07539233Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
24
Tianjin
2026-04-15
Not yet open
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
NCT07585747Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
27
Shenzhen, Zhengzhou, Nanchang, Jinan, Tianjin
2026-04-15
Not yet open
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
NCT07485504Relapsed or Refractory Hematologic Malignancies
Tcelltech Inc.
Phase 1
15
Tianjin
2026-04-15
Not yet open
Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients
NCT07483671Bacterial Vaginosis
Chengdu Syncor Pharmaceutical Co., Ltd.
Phase 2
80
Tianjin
2026-04-15
Recruiting
Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
NCT07482592Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
156
Tianjin
2026-04-15
Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006Alopecia Areata
Eli Lilly and Company
Phase 2
60
Beijing, Shanghai, Tianjin
2026-04-14
Active, closed
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
NCT07663903Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Ganzhou, Guangzhou, Hefei, Huai'an, Jinan
2026-04-14
Recruiting
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
NCT07390383Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
110
Beijing, Shijiazhuang, Jinan, Qingdao, Taiyuan, Tianjin
2026-04-13
Recruiting
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
NCT07137637Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Hangzhou Polymed Biopharmaceuticals, Inc.
Phase 1
60
Tianjin
2026-04-10
Recruiting
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
NCT07555470Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2026-04-10
Recruiting
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
NCT07493161Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
110
Tianjin
2026-04-10
Recruiting
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
NCT07407283Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Chengdu, Tianjin
2026-04-08
Recruiting
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
NCT07479485Hepatocellular Carcinoma
Lepu Biopharma Co., Ltd.
Phase 1/2
160
Beijing, Fuzhou, Zhengzhou, Nanjing, Tianjin, Lishui
2026-04-08
Recruiting
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
NCT07495631Acute Lymphoblastic Leukemia, Adult
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
43
Tianjin
2026-04-08
Not yet open
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
NCT07372079Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2026-04-05
Recruiting
A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
NCT07243340Glioma, Malignant
ImmVira Pharma Co. Ltd
Phase 1/2
36
Tianjin
2026-04-03
Recruiting
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
NCT07255872Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
216
Tianjin
2026-04-02
Recruiting
Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient Adherence
NCT07817056Breast Cancer, Hyperglycemia
Tianjin Medical University Cancer Institute and Hospital
Observational
100
Tianjin
2026-04-01
Recruiting
HCCANANO-HOPE1: IRE After Chemotherapy for Locally Advanced Unresectable Perihilar Cholangiocarcinoma
NCT07795619IRE
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2026-04-01
Not yet open
Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis
NCT07495150Blood-Brain Barrier, Bacterial Meningitis
yilong Wang
Not applicable
86
Beijing, Kaifeng, Xinxiang, Zhengzhou, Linyi, Tianjin
2026-04-01
Not yet open
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
NCT07379398NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
28
Tianjin
2026-04-01
Not yet open
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
NCT07531979ESCC, Tislelizumab, Chemotherapy, Becotatug Vedotin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
93
Tianjin
2026-04-01
Recruiting
Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain
NCT07490938Breast Cancer Survivors, Endocrine Therapy-Induced Joint Pain
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
200
Wuhan, Tianjin, Xining
2026-04-01
Not yet open
Effect of 37โ„ƒ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma
NCT03104569Cholangitis
Hepatopancreatobiliary Surgery Institute of Gansu Province
Not applicable
100
Lanzhou, Xi'an, Tianjin
2026-04-01
Not yet open
Normal Saline Infusion After Intravenous Thrombolysis in Stroke
NCT07497542Brain Infarction
Tianjin Medical University General Hospital
Phase 3
752
Tianjin
2026-04
Not yet open
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
NCT07539610B-Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
9
Tianjin
2026-04
Not yet open
Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
NCT07481903Psychoneurological Symptom Cluster(Pain, Insomnia, Anxiety, Fatigue, Depression, Subjective Cognitive Decline), Pain, Insomnia, Anxiety
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
228
Beijing, Nanjing, Qingdao, Tianjin
2026-04
Not yet open
FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis
NCT07485842Chronic Endometritis
Tianjin Medical University
Phase 4
300
Tianjin
2026-04
Recruiting
Acupuncture for Post-Stroke Dysphagia: A Clinical Study
NCT07493902Post-stroke Dysphagia, Acupuncture
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
3,232
Tianjin
2026-04
Not yet open
Electroacupuncture for the Prevention of Recurrent Lower Urinary Tract Infection in Women
NCT07507851Urinary Tract Infections, Recurrent, Electroacupuncture, Randomized Controlled Trial (RCT)
Yanjun Zhang, Baoyan Liu
Not applicable
312
Beijing, Tianjin
2026-04
Recruiting
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
NCT07589205Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 1
493
Tianjin
2026-03-31
Recruiting
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
NCT07455734Advanced Solid Tumor Cancer
BioNTech SE
Phase 1/2
533
Chongqing, Guangzhou, Hangzhou, Shanghai, Tianjin
2026-03-30
Recruiting
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
NCT07560488HCC - Hepatocellular Carcinoma, Conversion Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
43
Tianjin
2026-03-30
Recruiting
The Effect of Braun Anastomosis on Delayed Gastric Emptying (DGE) in Reconstruction After Pancreaticoduodenectomy
NCT07681128Periampullary Carcinoma Resectable
Tianjin Medical University Cancer Institute and Hospital
Not applicable
264
Tianjin
2026-03-30
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb
Phase 1/2
474
Beijing, Guangzhou, Tianjin, Harbin, Changsha Shi, Nanjing, Shanghai Shi
2026-03-26
Recruiting
A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis
NCT07443306MF
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
64
Chengdu, Tianjin
2026-03-18
Recruiting
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
NCT07777861Primary Open-Angle Glaucoma, Optic Nerve Injury
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Phase 2
90
Beijing, Guangzhou, Shantou, Changsha, Tianjin, Hangzhou, Wenzhou
2026-03-18
Recruiting
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
NCT07529782Multiple Myeloma and Other Plasma Cell Neoplasms
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
15
Beijing, Suzhou, Jinan, Tianjin, Hangzhou
2026-03-17
Recruiting
Investigating the Efficacy and Mechanisms of Individualized tACS Targeting Anhedonia in Late-Life Depression
NCT07637773Late-Life Depression, Anhedonia
Jie Li
Not applicable
80
Tianjin
2026-03-16
Recruiting
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07475403Bladder Cancer, Liquid Biopsy, Immunotherapy
Tianjin Medical University Second Hospital
Phase 2
53
Tianjin, Xingtai
2026-03-16
Recruiting
Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
NCT07545395Hemophilia A or B
Suzhou Alphamab Co., Ltd.
Phase 3
70
Tianjin
2026-03-13
Recruiting
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
NCT07457528Resectable Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
46
Tianjin
2026-03-12
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
Pfizer
Phase 1/2
132
Beijing, Nanjing, Tianjin, Ningbo
2026-03-11
Recruiting
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT07452198Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
358
Tianjin
2026-03-09
Recruiting
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
NCT07436741Pancreatic Cancer, Adult
Tianjin Medical University Cancer Institute and Hospital
Phase 3
106
Tianjin
2026-03-03
Not yet open
A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia
NCT07441980Relapsed/Refractory Acute Myeloid Leukemia(AML)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
18
Tianjin
2026-03-02
Recruiting
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
NCT07506109BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
49
Beijing, Wuhan, Chengdu, Tianjin
2026-03-01
Recruiting
PCC Treatment for Hemophilia Patients With Inhibitor๏ผˆ2022PCC-A๏ผ‰
NCT07406139Hemophilia, Inhibitors
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
30
Tianjin
2026-03-01
Recruiting
Impact of Pringle Maneuver on Postoperative Gallbladder Diseases After Hepatectomy
NCT07452848Gallbladder Diseases, Cholelithiasis
West China Hospital
Observational
2,000
Hefei, Chongqing, Guangzhou, Harbin, Wuhan, Nanjing, Tianjin
2026-03-01
Not yet open
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese Subjects
NCT07422142Delirium
Kunming Pharmaceuticals, Inc.
Phase 1
54
Tianjin
2026-03-01
Active, closed
A Pan-Cancer Retrospective Study on the Relationship Between Tumor Microenvironment Composition and Efficacy of Antibody-Based Antitumor Therapy
NCT07584044Tumor Microenvironment, Antibody
Tianjin Medical University Cancer Institute and Hospital
Observational
300
Tianjin
2026-03-01
Recruiting
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT07362238Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
122
Tianjin
2026-03
Recruiting
Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
NCT07441499Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer, Liquid Biopsy
Tianjin Medical University Second Hospital
Observational
300
Tianjin
2026-03
Recruiting
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07362199Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-03
Not yet open
Universal Chimeric Antigen Receptor T-Cell ๏ผˆUCAR T-cell๏ผ‰ Therapy Targeting CD19/ BCMA๏ผˆQT-019C๏ผ‰ in Patients With r/ r Neurological Autoimmune Diseases
NCT07392528Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis, Myasthenia Gravis
Tianjin Huanhu Hospital
Phase EARLY_PHASE1
15
Tianjin
2026-03
Recruiting
Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)
NCT07386015Freezing of Gait, Parkinson's Disease, Parkinsonism, Vascular Parkinsonism
Tianjin Huanhu Hospital
Observational
700
Tianjin
2026-02-28
Recruiting
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
NCT07409246Multiple Myeloma
AbbVie
Phase 1
127
Tianjin
2026-02-27
Recruiting
Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
NCT07471516Congenital Dyserythropoietic Anemia (CDA)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
2
Tianjin
2026-02-25
Active, closed
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
NCT07646717Intrahepatic Cholangiocarcinoma (Icc)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-02-24
Recruiting
Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
NCT07461116Aplastic Anaemia
Institute of Hematology & Blood Diseases Hospital, China
Observational
200
Tianjin
2026-02-23
Recruiting
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
NCT06992076Hemophilia
Institute of Hematology & Blood Diseases Hospital, China
Observational
100
Xiamen, Tianjin
2026-02-15
Recruiting
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
NCT07317700MF
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3
105
Chengdu, Tianjin
2026-02-13
By invitation
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
NCT07456774Type 2 Diabetes
Novo Nordisk A/S
Observational
100,000
Tianjin
2026-02-13
Rows per page Showing 101–200 of 940
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 940 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

601 of the 940 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 153 have not yet opened recruitment, 162 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.